TIDMPRTC
RNS Number : 8479X
PureTech Health PLC
10 May 2016
10 May 2016
PureTech Health plc
Results of Annual General Meeting
The Annual General Meeting of PureTech Health plc ("PureTech",
LSE: PRTC) plc was held at 5.00pm on Monday 9 May 2016. All of the
resolutions proposed at the Annual General Meeting were duly passed
by the shareholders on a poll.
The results of the poll, incorporating the proxy votes lodged in
advance of the meeting, are set out below.
Resolutions For % Against % Withheld Total
votes
cast
------------------------ ------------ ------- ----------- ----- ---------- ------------
001. To receive
the Company's
Annual Report
and Accounts
for year end
31 December
2015 185,702,295 100.00 0 0.00 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
002. To approve
the Directors'
Remuneration
Report 179,445,048 99.65 624,012 0.35 5,633,235 180,069,060
------------------------ ------------ ------- ----------- ----- ---------- ------------
003. To approve
the Directors'
Remuneration
Policy 179,963,800 99.94 105,260 0.06 5,633,235 180,069,060
------------------------ ------------ ------- ----------- ----- ---------- ------------
004. To elect
Mr. Joichi
Ito as a Director 185,183,543 99.72 518,752 0.28 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
005. To elect
Dr. Raju Kucherlapati
as a Director 184,883,224 99.56 819,071 0.44 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
006. To elect
Dr. John LaMattina
as a director 185,702,295 100.00 0 0.00 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
007. To elect
Dame Marjorie
Scardino as
a director 185,624,655 99.96 77,640 0.04 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
008. To elect
Mr. Christopher
Viehbacher
as a director 185,624,655 99.96 77,640 0.04 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
009. To elect
Dr. Robert
Langer as
a director 184,920,864 99.58 781,431 0.42 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
010. To elect
Dr. Bennett
Shapiro as
a director 184,960,864 99.60 741,431 0.40 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
011. To elect
Ms. Daphne
Zohar as a
director 185,694,032 99.99 8,263 0.01 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
012. To elect
Mr. Stephen
Muniz as a
director 185,175,280 99.72 527,015 0.28 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
013. To reappoint
KPMG LLP as
Auditors of
the Company 185,352,712 99.81 349,583 0.19 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
014. To authorize
the Board
of Directors
to determine
the Auditor's
remuneration 185,352,712 99.81 349,583 0.19 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
015. To authorize
the allotment
of shares 175,240,183 94.37 10,462,112 5.63 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
016. To dis-apply
pre-emption
rights 179,246,480 96.97 5,592,091 3.03 863,724 184,838,571
------------------------ ------------ ------- ----------- ----- ---------- ------------
017. To authorize
market purchase
of own shares 185,702,295 100.00 0 0.00 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
018. To authorize
general meetings
to be called
on not less
than 14 clear
days' notice 184,493,872 99.35 1,208,423 0.65 0 185,702,295
------------------------ ------------ ------- ----------- ----- ---------- ------------
VOTES OF SHAREHOLDERS EXCLUDING CONTROLLING SHAREHOLDER
As the Company has a controlling shareholder, Invesco Asset
Management Limited, as defined in the Financial Conduct Authority's
Listing Rules, each resolution to elect an independent director
(resolutions 5,6,7 and 8) have under Listing Rule 9.2.2E been
approved by a majority of the votes cast by:
-- the shareholders of the Company as a whole; and
-- the independent shareholders of the Company, that is, all the
shareholders entitled to vote on each resolution excluding the
controlling shareholder as shown below.
Resolutions For % Against % Withheld Total
votes
cast
------------------------ ------------ ------- -------- ----- --------- ------------
005. To elect
Dr. Raju Kucherlapati
as a Director 108,843,564 99.25 819,071 0.75 0 109,662,635
------------------------ ------------ ------- -------- ----- --------- ------------
006. To elect
Dr. John LaMattina
as a director 109,662,635 100.00 0 0.00 0 109,662,635
------------------------ ------------ ------- -------- ----- --------- ------------
007. To elect
Dame Marjorie
Scardino as
a director 109,584,995 99.93 77,640 0.07 0 109,662,635
------------------------ ------------ ------- -------- ----- --------- ------------
008. To elect
Mr. Christopher
Viehbacher
as a director 109,584,995 99.93 77,640 0.07 0 109,662,635
------------------------ ------------ ------- -------- ----- --------- ------------
Notes:
1. A vote "Withheld" is not a vote in law and is not counted in
the calculation of the votes "For" or "Against" a resolution.
2. As at 9 May 2016, the number of issued shares in the Company
was 237,387,951 ordinary shares, which was the total number of
shares entitling the holders to attend and vote for or against all
the resolutions at the AGM. In accordance with the Company's
Articles of Association, on a poll every member present in person
or by proxy has one vote for every share held.
The full text of the resolutions may be found in the Notice of
the Annual General Meeting, copies of which are available on both
the Company's website www.puretechhealth.com and on the National
Storage Mechanism.
In accordance with Listing Rule 9.6.2, a copy of the
resolutions, other than those concerning ordinary business has been
submitted to the National Storage Mechanism and will shortly be
available for inspection at: www.morningstar.co.uk/uk/NSM.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a
cross-disciplinary healthcare company developing innovative
products that could improve the lives of billions of patients.
PureTech is focused on areas of growing scientific and technical
insights that it believes are at an important inflection point,
including the central nervous, gastro-intestinal and immune
systems, and the interactions and signalling between them. PureTech
has a pipeline of more than 30 programmes and has approximately 20
clinical studies across its pipeline, targeting multi-billion
dollar market opportunities. PureTech's advanced programmes include
five with human proof-of-concept and multiple with pivotal or
registration study readouts in the next two years. PureTech's
leading team and board, along with an advisory network of more than
60 expert founder-scientists and advisors across multiple
disciplines, gives PureTech access to potentially ground-breaking
science and technological innovation. With healthcare undergoing
major transformation, PureTech believes it is well positioned to
develop and launch medicines for the 21st century. For more
information, visit http://www.puretechhealth.com and connect with
us on Twitter.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Enquiries
PureTech
Allison Mead, Associate Director, +1 617 651
Communications and Investor Relations 3156
FTI Consulting (Communications adviser
to PureTech)
Ben Atwell +44 (0) 20
Matthew Cole 3727 1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGAKKDQABKDPPD
(END) Dow Jones Newswires
May 10, 2016 12:49 ET (16:49 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024
